BR100 Increased By (0.44%)
BR30 Increased By (1.39%)
KSE100 Increased By (0.62%)
KSE30 Increased By (0.61%)
BECO 5.43 Decreased By ▼ -0.06 (-1.09%)
BML 55.69 Decreased By ▼ -1.07 (-1.89%)
BOP 35.38 Increased By ▲ 0.26 (0.74%)
CNERGY 8.20 Increased By ▲ 0.05 (0.61%)
DCL 11.55 Increased By ▲ 0.04 (0.35%)
FCCL 58.36 Increased By ▲ 1.61 (2.84%)
FCSC 5.12 Decreased By ▼ -0.03 (-0.58%)
FFL 17.84 Decreased By ▼ -0.04 (-0.22%)
FNEL 1.25 No Change ▼ 0.00 (0%)
HUMNL 11.07 Decreased By ▼ -0.05 (-0.45%)
KEL 8.75 Increased By ▲ 0.33 (3.92%)
KOSM 6.69 Increased By ▲ 0.11 (1.67%)
MLCF 107.15 Increased By ▲ 3.85 (3.73%)
NBP 201.73 Increased By ▲ 1.55 (0.77%)
PACE 11.30 Increased By ▲ 0.01 (0.09%)
PAEL 44.49 Increased By ▲ 1.02 (2.35%)
PIAHCLA 29.41 Increased By ▲ 1.92 (6.98%)
PIBTL 18.64 Increased By ▲ 0.94 (5.31%)
PPL 247.98 Increased By ▲ 3.66 (1.5%)
PRL 35.29 Decreased By ▼ -0.14 (-0.4%)
PTC 66.14 Increased By ▲ 0.79 (1.21%)
SEARL 95.49 Increased By ▲ 2.17 (2.33%)
SSGC 32.04 Decreased By ▼ -0.90 (-2.73%)
TELE 8.87 Decreased By ▼ -0.04 (-0.45%)
THCCL 66.61 Decreased By ▼ -0.11 (-0.16%)
TPLP 10.57 Decreased By ▼ -0.26 (-2.4%)
TREET 25.30 Increased By ▲ 0.18 (0.72%)
TRG 64.40 Decreased By ▼ -0.50 (-0.77%)
WAVES 10.90 Decreased By ▼ -0.03 (-0.27%)
WTL 1.26 Increased By ▲ 0.01 (0.8%)
World

EU regulator could approve Covid vaccines 'late 2020, early 2021'

  • The Amsterdam-based EMA is carrying out "rolling reviews" designed to speed up vaccine approval times on three candidates: Pfizer-BioNTech, Moderna, and Oxford University-AstraZeneca.
Published November 23, 2020 Updated November 23, 2020 05:03pm
By

THE HAGUE: Europe's medicines regulator said Monday that it could approve the first coronavirus vaccines late this year or early next, as it evaluates the most promising candidates.

The clarification came after EU Commission president Ursula von der Leyen said last week that the watchdog could give the green light for vaccines tested by Pfizer-BioNTech and by Moderna before the end of December.

"It is difficult to predict timelines for the authorisation of vaccines precisely at this stage, as the data are still coming in and the rolling reviews are currently ongoing," the European Medicines Agency said in an emailed statement to AFP.

"Depending on how the evaluation progresses, EMA could indeed be in a position to conclude evaluation for the most advanced candidates towards the end of this year or the beginning of next."

The Amsterdam-based EMA is carrying out "rolling reviews" designed to speed up vaccine approval times on three candidates: Pfizer-BioNTech, Moderna, and Oxford University-AstraZeneca.

US giant Pfizer and Germany's BioNTech has already sent data to the EMA after the companies said clinical trials showed their experimental vaccine is 95 percent effective.

US-based Moderna meanwhile says its vaccine is 94.5 percent effective, and Oxford and AstraZeneca said Monday that theirs showed 70 percent effectiveness, rising to 90 percent depending on the type of dosage.

Several European countries have already unveiled strategies to roll out coronavirus vaccines to large parts of their populations as soon as they are approved by the EMA.

Comments

Comments are closed for this article.